Agios Pharmaceuticals, Inc. (AGIO) Reaches $56.19 After 7.00% Down Move; Chemung Financial (CHMG) Shorts Increased By 38.3%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Chemung Financial Corp (NASDAQ:CHMG) had an increase of 38.3% in short interest. CHMG’s SI was 32,500 shares in April as released by FINRA. Its up 38.3% from 23,500 shares previously. With 8,900 avg volume, 4 days are for Chemung Financial Corp (NASDAQ:CHMG)’s short sellers to cover CHMG’s short positions. The SI to Chemung Financial Corp’s float is 1.01%. The stock increased 1.15% or $0.56 during the last trading session, reaching $49.9. About 5,493 shares traded. Chemung Financial Corporation (NASDAQ:CHMG) has risen 10.20% since April 17, 2018 and is uptrending. It has outperformed by 5.83% the S&P500. Some Historical CHMG News: 17/05/2018 – Chemung Financial Announces Quarterly Dividend; 05/03/2018 – Chemung Financial: Change Resulted From Internal Control Review Proces; 05/03/2018 – Chemung Financial Reports Revised 4Q Earning; 05/03/2018 – Chemung Financial: ‘Disappointed’ by Added Provision, Will ‘Vigorously Pursue Recovery’ of Identified Loan; 05/03/2018 Chemung Financial 4Q Loss/Shr 45c; 18/04/2018 – Chemung Financial 1Q EPS 92c; 21/04/2018 – DJ Chemung Financial Corporation, Inst Holders, 1Q 2018 (CHMG)

The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a huge mover today! The stock decreased 5.91% or $3.53 during the last trading session, reaching $56.19. About 280,859 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has declined 17.41% since April 17, 2018 and is downtrending. It has underperformed by 21.78% the S&P500. Some Historical AGIO News: 06/04/2018 – Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma; 25/04/2018 – EC OKS BRISTOL-MYERS SQUIBB’S OPDIVO; 06/03/2018 – Bristol-Myers: Opdivo Dosing Now Includes 480 Mg Infused Every Four Weeks for Majority of Approved Indications; 25/04/2018 – EC OKS BMY’S OPDIVO FOUR-WEEK DOSING FOR ADVANCED MELANOMA; 16/04/2018 – Combination Of Pembrolizumab And Chemotherapy Doubles Survival In Patients With Metastatic Lung Cancer; 06/03/2018 – FDA approves new dosing for Bristol-Myers Squibb’s Opdivo; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 08/03/2018 – REG-Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD; 13/04/2018 – BMY: OPDIVO SHOWED STAT SIG BENEFIT VERSUS DOCETAXELThe move comes after 8 months negative chart setup for the $3.28B company. It was reported on Apr, 17 by We have $52.26 PT which if reached, will make NASDAQ:AGIO worth $229.67M less.

Chemung Financial Corporation operates as the holding firm for Chemung Canal Trust Company that provides a range of banking, financing, fiduciary, and other financial services primarily in New York. The company has market cap of $241.27 million. It offers demand, savings, and time deposits; non-interest- and interest-bearing checking accounts; and insured money market accounts. It has a 12.28 P/E ratio. The firm also provides commercial and agricultural loans primarily consisting of loans to small to mid-sized businesses; commercial mortgage loans; residential mortgage loans; and consumer loans, including home equity lines of credit and home equity loans, as well as letters of credit.

Investors sentiment decreased to 0.95 in Q4 2018. Its down 0.64, from 1.59 in 2018Q3. It fall, as 5 investors sold Chemung Financial Corporation shares while 17 reduced holdings. 8 funds opened positions while 13 raised stakes. 1.66 million shares or 1.35% more from 1.64 million shares in 2018Q3 were reported. 4,703 are held by Bank & Trust Of America Corp De. Chemung Canal Tru invested in 4.88% or 412,274 shares. Morgan Stanley has invested 0% of its portfolio in Chemung Financial Corporation (NASDAQ:CHMG). Meeder Asset Inc holds 92 shares. Charles Schwab Invest Management Inc reported 8,070 shares. Bessemer Grp Inc holds 0% in Chemung Financial Corporation (NASDAQ:CHMG) or 5,700 shares. Moreover, Wellington Mngmt Grp Limited Liability Partnership has 0% invested in Chemung Financial Corporation (NASDAQ:CHMG) for 34,567 shares. Northern, Illinois-based fund reported 35,723 shares. 52,128 are owned by State Street. First Manhattan Comm stated it has 0.02% in Chemung Financial Corporation (NASDAQ:CHMG). Deutsche National Bank Ag holds 0% of its portfolio in Chemung Financial Corporation (NASDAQ:CHMG) for 6,388 shares. Barclays Plc holds 0% or 95 shares in its portfolio. California Public Employees Retirement Systems stated it has 0% in Chemung Financial Corporation (NASDAQ:CHMG). Private Advisor Ltd Llc owns 7,619 shares. 452 were accumulated by Legal & General Grp Public Limited Com.

More notable recent Chemung Financial Corporation (NASDAQ:CHMG) news were published by: which released: “Chemung Financial (CHMG) to Report Q1 Results: Wall Street Expects Earnings Growth – Nasdaq” on April 10, 2019, also with their article: “Chemung Financial (CHMG) Upgraded to Strong Buy: Here’s Why – Nasdaq” published on March 21, 2019, published: “New Strong Buy Stocks for March 26th – Nasdaq” on March 26, 2019. More interesting news about Chemung Financial Corporation (NASDAQ:CHMG) were released by: and their article: “New Strong Buy Stocks for March 21st – Nasdaq” published on March 21, 2019 as well as‘s news article titled: “Chemung Financial Corp (CHMG) Ex-Dividend Date Scheduled for March 15, 2019 – Nasdaq” with publication date: March 14, 2019.

Since October 24, 2018, it had 4 insider buys, and 0 sales for $126,621 activity. Gonick Denise V also bought $41,760 worth of Chemung Financial Corporation (NASDAQ:CHMG) shares. $27,986 worth of Chemung Financial Corporation (NASDAQ:CHMG) shares were bought by STREETER JEFFREY B. Tranter G. Thomas Jr. had bought 500 shares worth $20,750.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on May, 3. They expect $-1.73 EPS, down 6.13% or $0.10 from last year’s $-1.63 per share. After $-1.58 actual EPS reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 9.49% negative EPS growth.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: which released: “Interesting AGIO Put And Call Options For November 15th – Nasdaq” on April 01, 2019, also with their article: “New marketing chief at Agios – Seeking Alpha” published on April 02, 2019, published: “Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy – Nasdaq” on March 26, 2019. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: and their article: “Analysis: Positioning to Benefit within Valvoline, Alliance Data, CBS, BBX Capital, Agios Pharmaceuticals, and MICT — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” published on April 15, 2019 as well as‘s news article titled: “Agios’ Tibsovo a Breakthrough Therapy for certain type of AML – Seeking Alpha” with publication date: March 26, 2019.

Since November 5, 2018, it had 0 insider purchases, and 1 sale for $209,071 activity. Biller Scott also sold $209,071 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, November 5.

Among 2 analysts covering Agios Pharma (NASDAQ:AGIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharma had 7 analyst reports since February 15, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Friday, February 15 by Canaccord Genuity. The firm earned “Buy” rating on Friday, February 15 by Leerink Swann.

Chemung Financial Corporation (NASDAQ:CHMG) Institutional Positions Chart